Sullivan, Bruyette, Speros & Blaney’s DexCom DXCM Stock Holding History

Sullivan, Bruyette, Speros & Blaney’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$127K	Buy	1,416 +8	+0.6%	+$751	0.01%	376
2020 Q4	$130K	Sell	1,408 -296	-17%	-$26.4K	0.01%	357
2020 Q3	$176K	Sell	1,704 -224	-12%	-$23.4K	0.01%	269
2020 Q2	$195K	Buy	1,928 +224	+13%	+$20K	0.01%	241
2020 Q1	$115K	Buy	+1,704	New	+$106K	0.01%	279

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPC

Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Sullivan, Bruyette, Speros & Blaney's DXCM Position: Q1 2021 in Review

Sullivan, Bruyette, Speros & Blaney increased its DexCom (DXCM) stake by 0.57% in Q1 2021, buying an estimated $751 and bringing the position to 1,416 shares worth $127K. The position accounts for 0.01% of the portfolio, ranked #376.

Sullivan, Bruyette, Speros & Blaney first reported a position in DXCM in Q1 2020 and has held it in 5 quarters since. The position peaked at $195K in Q2 2020. 730 funds tracked by Wall St. Rank hold DXCM as of Q1 2021.

Sullivan, Bruyette, Speros & Blaney held 1,416 shares of DexCom worth $127K as of Q1 2021.
Sullivan, Bruyette, Speros & Blaney bought 8 DexCom shares in Q1 2021, an estimated $751.
DexCom made up 0.01% of Sullivan, Bruyette, Speros & Blaney's portfolio in Q1 2021, its #376 holding.
Sullivan, Bruyette, Speros & Blaney first reported a position in DexCom in Q1 2020 and has held it in 5 quarters since.
Sullivan, Bruyette, Speros & Blaney's DexCom position peaked at $195K in Q2 2020.
730 funds tracked by Wall St. Rank held DexCom as of Q1 2021.

Based on Sullivan, Bruyette, Speros & Blaney's 13F filing for Q1 2021, filed 10 May 2021.